Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

TALS


Top 10 Correlated ETFs

TALS


Top 10 Correlated Stocks

TALS


In the News

07:00 13 Aug 2022 TALS

Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.

07:00 13 Aug 2022 TALS

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.

04:01 13 Aug 2022 TALS

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.

04:01 13 Aug 2022 TALS

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences:

07:00 13 Aug 2022 TALS

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

07:00 13 Aug 2022 TALS

Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.

07:00 13 Aug 2022 TALS

Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

07:00 13 Aug 2022 TALS

Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

04:36 13 Aug 2022 TALS

Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting

BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.

04:01 13 Aug 2022 TALS

Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021, and provided an update on its business.

Financial details

Company Rating
Buy
Market Cap
187.82M
Income
-56.79M
Revenue
0
Book val./share
5.52
Cash/share
5.5
Dividend
-
Dividend %
-
Employees
121
Optionable
No
Shortable
Yes
Earnings
-
P/E
-3.38
Forward P/E
-
PEG
-0.79
P/S
-
P/B
0.85
P/C
0.88
P/FCF
-3.97
Quick Ratio
27.96
Current Ratio
28.32
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
110.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
28.51%
-
-
-
-
SMA20
52.63%
SMA50
-39.74%
SMA100
-40.89%
Inst Own
100%
Inst Trans
26.55%
ROA
-24%
ROE
-23%
ROC
-0.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
40.31M
Shs Float
13.63M
-
-
-
-
Target Price
-
52W Range
2.04-17.485
52W High
-71.47%
52W Low
+142.5%
RSI
53.95
Rel Volume
0.4
Avg Volume
197.93K
Volume
79.42K
Perf Week
1.46%
Perf Month
7.54%
Perf Quarter
-40.2%
Perf Half Y
-49.84%
-
-
-
-
Beta
-
-
-
Volatility
0.22%, 0.76%
Prev Close
3.41%
Price
4.85
Change
2.32%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2021-12-31
Revenue per share
0
Net income per share
-2.26
Operating cash flow per share
-1.89
Free cash flow per share
-1.89
Cash per share
11.51
Book value per share
11.46
Tangible book value per share
11.46
Share holders equity per share
11.46
Interest debt per share
-0.02
Market cap
192.43M
Enterprise value
173.81M
P/E ratio
-4.02
Price to sales ratio
0
POCF ratio
-4.81
PFCF ratio
-4.81
P/B Ratio
0.79
PTB ratio
0.79
EV to sales
0
Enterprise value over EBITDA
-3.66
EV to operating cash flow
-4.35
EV to free cash flow
-4.35
Earnings yield
-0.25
Free cash flow yield
-0.21
Debt to equity
0
Debt to assets
0.03
Net debt to EBITDA
0.39
Current ratio
30.86
Interest coverage
145.73
Income quality
0.84
Dividend Yield
0
Payout ratio
0
Sales general and administrative to revenue
0
Research and developement to revenue
0
Intangibles to total assets
0
Capex to operating cash flow
0
Capex to revenue
0
Capex to depreciation
-0.05
Stock based compensation to revenue
0
Graham number
24.12
ROIC
-0.2
Return on tangible assets
-0.19
Graham Net
11.11
Working capital
238.53M
Tangible asset value
0
Net current asset value
237.9M
Invested capital
0
Average receivables
0
Average payables
1.66M
Average inventory
0
Days sales outstanding
0
Days payables outstanding
0
Days of inventory on hand
0
Receivables turnover
0
Payables turnover
0
Inventory turnover
0
ROE
-0.2
Capex per share
0

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
0000
Net income per share
-0.41-0.32-0.35-0.45
Operating cash flow per share
-0.4-0.25-0.24-0.4
Free cash flow per share
-0.41-0.27-0.21-0.43
Cash per share
9.736.2665.5
Book value per share
9.776.295.975.52
Tangible book value per share
9.776.295.975.52
Share holders equity per share
9.776.295.975.52
Interest debt per share
00-0.010.09
Market cap
402.11M551.48M621.84M403.25M
Enterprise value
365.81M524.17M603.22M383.85M
P/E ratio
-8.86-10.65-10.92-5.52
Price to sales ratio
0000
POCF ratio
-36.62-54.45-63.26-24.77
PFCF ratio
-35.53-50.8-72.46-22.88
P/B Ratio
1.52.162.561.78
PTB ratio
1.52.162.561.78
EV to sales
0000
Enterprise value over EBITDA
-33.49-40.66-41.93-21.41
EV to operating cash flow
-33.31-51.75-61.37-23.58
EV to free cash flow
-32.32-48.29-70.29-21.78
Earnings yield
-0.03-0.02-0.02-0.05
Free cash flow yield
-0.03-0.02-0.01-0.04
Debt to equity
0000.01
Debt to assets
0.020.020.030.05
Net debt to EBITDA
3.322.121.291.08
Current ratio
58.0351.8330.8628.32
Interest coverage
0044.13-118.8
Income quality
0.970.780.690.89
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0.030.07-0.120.08
Capex to revenue
0000
Capex to depreciation
-2.52-4.356.46-2.75
Stock based compensation to revenue
0000
Graham number
9.556.716.867.44
ROIC
-0.04-0.05-0.06-0.08
Return on tangible assets
-0.04-0.05-0.06-0.08
Graham Net
9.536.125.795.23
Working capital
265.81M253.25M238.53M220.35M
Tangible asset value
0000
Net current asset value
265.01M252.55M237.9M217.2M
Invested capital
0000.02
Average receivables
0000
Average payables
1.91M1.87M2.56M3.02M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.04-0.05-0.06-0.08
Capex per share
-0.01-0.020.03-0.03

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap